PR83829

NEW YORK, Apr. 28, 2020 /PRNewswire=KYODO JBN/--

- Industry veteran to build on AiCure's ten years of market success and extend

AI platform to digital biomarkers for holistic patient health

- Continued corporate growth and platform milestones drive 2020 momentum

AiCure (

https://c212.net/c/link/?t=0&l=en&o=2787735-1&h=3494405458&u=http%3A%2F%2Fwww.aicure.com%2F&a=AiCure

), an AI and advanced data analytics company focused on improving clinical

trials, today announced Ed Ikeguchi, M.D. as its Chief Executive Officer (CEO).

Formerly serving as the company's Chief Medical Officer (CMO) and President,

Dr. Ikeguchi's appointment as CEO will advance AiCure's commitment to improving

holistic health through an understanding of the science behind human responses

to illness and treatment. With today's announcement (

https://c212.net/c/link/?t=0&l=en&o=2787735-1&h=1422592979&u=https%3A%2F%2Faicure.com%2Faicure-industry-first-computer-vision-to-capture-dbm%2F&a=today%27s+announcement

) of digital biomarkers, AiCure is delivering on this vision.

Logo - https://mma.prnewswire.com/media/1022858/AiCure_Logo.jpg

Prior to joining as AiCure's CMO in 2018, Dr. Ikeguchi co-founded Medidata

Solutions, where he grew the company from its inception to its initial public

offering in 2009 while serving as its CEO from 1999-2001 and its CMO from

2001-2009. Dr. Ikeguchi's extensive experience in both the C-suite and in

clinical environments, including his understanding of the many pain points of

patient engagement, positions him well to lead the company in its next phase.

Dr. Ikeguchi takes the helm of AiCure, which for ten years, has enhanced the

quality of clinical trial data by providing real-time monitoring of patient

dosing and behavior, enabling smaller, faster trials. AiCure has established

its value to pharmaceutical companies and healthcare organizations by providing

novel insights into patient behavior, allowing them to measure and modify it

for optimal care. Capitalizing on the wealth of behavioral data AiCure has

stored and analyzed, Dr. Ikeguchi will expand the company's footprint in

digital biomarking to identify non-obvious patient reactions to capture a

complete picture of complex human behavior. Further equipping clients with an

understanding of such behavioral trends will empower real-time, objective

observations of people in their natural environment that can help improve

patient and trial outcomes.

"The traditional brick-and-mortar blueprint of healthcare and clinical trials

only lends itself to transactional patient relationships and blind spots

between in-person visits. At AiCure, we aim to shift this mindset and achieve

continuous line-of-sight into an individual's wellbeing," said Dr. Ed Ikeguchi,

CEO of AiCure. "It is my privilege to lead the company in its next chapter as

we work toward holistic health delivery, deepen our understanding of patients'

lived experience, and elevate the credibility of clinical trial results. We are

poised to build on our strong momentum and further make our mark in patient

care and drug development."

Pillars of Success Drive 2020 Growth

In addition to Dr. Ikeguchi's appointment, AiCure has achieved several

milestones for a strong 2020 performance to-date, including:

-- Sustained corporate momentum:

-- Addition of Vidhi Goel as the new vice president of marketing,

leveraging her two decades of industry experience to address

customer needs

-- Continued revenue growth across both new clients and repeat

business from top-20 pharma companies, including 200% growth in

digital biomarker customers

-- Ongoing collaborations with sponsors to develop predictive

analytics to build industry-leading tools for monitoring

participant and site performance

-- Expansion of platform:

-- Official launch of the company's first digital biomarker platform

to remotely detect subtle changes in a patient's condition

-- New caregiver functionality that allows for notifications and text

alerts to be shared with approved caregivers to enhance the

platform's use in pediatric trials and for conditions like

Parkinson's and Alzheimer's Disease

-- Introduction of home visit workflow to support in-home nurse

visits, reducing the need for a patient to go into a clinic

-- New electronic patient reported outcome (ePRO) capabilities

that increase patient engagement and aim to replicate traditional

clinician assessments

-- Improved technology features:

-- Enhanced video review capabilities to better monitor for

intentional non-adherence in high-risk studies

-- Deployment of single sign-on capability and availability of

the platform in four additional languages, bringing total

availability to 45 languages

-- Expanded analytics engine to extend continuous learning

capabilities of machine learning platform

-- Customized reporting that analyzes customer study performance

against industry benchmarks.

About AiCure

AiCure is an AI and advanced data analytics company that monitors patient

behavior and enables remote patient engagement in clinical trials. AiCure

improves predictability of study timelines, reduces costs and accelerates

timelines through remote patient engagement and assessments, including

measuring digital biomarkers and real-time monitoring of patient dosing.

Founded in 2010 and funded by the National Institutes of Health (NIH) and

leading institutional investors, AiCure has more than 65 issued patents and

works with global clients in over 30 countries. AiCure is globally recognized

and is a recipient of the Scrip Award, AI 100 and Digital Health 150. For more

information, please visit www.aicure.com.

Media Contact

Siobhan Nguyen

aicure@fleishman.com

+1-617-986-5784

SOURCE: AiCure